Prosecution Insights
Prosecution Insights
12 pending office actions • 10 art units • 12 examiners • 0 of 12 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 7 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 7 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 5 (42%) |
| Double-patenting only | 2 (17%) |
| Multi-statute (no §101) | 5 (42%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 59.0% | +29.8% |
| SHUPE, ELIZABETH A | 1 | 65.7% | +46.8% |
| SZNAIDMAN, MARCOS L | 1 | 37.2% | +16.0% |
| EDWARDS, PHILIP CHARLES | 1 | 85.4% | +14.8% |
| PAULUS, ERIN VIRGINIA | 1 | 25.0% | +92.3% |
| NGUYEN, HUONG Q | 1 | 45.7% | +44.6% |
| HIRAKIS, SOPHIA P | 1 | 52.2% | +73.3% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +69.0% |
| WEBSTER, KARMEL JOHANNA | 1 | 65.0% | +26.2% |
| GIBBS, TERRA C | 1 | 63.9% | +10.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | GIBBS, TERRA C | 10d overdue |
| 18002951 | Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18000011 | NONINVASIVE CRANIAL NERVE THERAPY | WEBSTER, KARMEL JOHANNA | 52d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 29d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | GIBBS, TERRA C | 10d overdue |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | — |
| 18543191 | CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY | SHUPE, ELIZABETH A | — |
| Art Unit | Apps |
|---|---|
| 3792 | 2 |
| 1643 | 1 |
| 1628 | 1 |
| 1631 | 1 |
| 3791 | 1 |
| 1623 | 1 |
| 1654 | 1 |
| 1635 | 1 |
| 1675 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | — | DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18543191 | CD38-NAD+ REGULATED METABOLIC AXIS IN ANTI-TUMOR IMMUNOTHERAPY | SHUPE, ELIZABETH A | 1643 | §103 | Non-Final OA | — | Pending | Dec 18, 2023 |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Aug 25, 2023 |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 1631 | §102§103§112 | Final Rejection | 29d overdue | Pending | Mar 31, 2023 |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 3791 | §103 | Non-Final OA | 29d overdue | Pending | Mar 28, 2023 |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Final Rejection | 78d overdue | Pending | Jan 17, 2023 |
| 18002951 | Use of Caveolin-1 Scaffolding Domain Peptides for Treating Disease and Disorders | DABKOWSKI, ERINNE R | 1654 | §103§112 | Final Rejection | — | Pending | Dec 22, 2022 |
| 18000011 | NONINVASIVE CRANIAL NERVE THERAPY | WEBSTER, KARMEL JOHANNA | 3792 | §103 | Final Rejection | 52d overdue | Pending | Nov 28, 2022 |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | GIBBS, TERRA C | 1635 | §102§103§112 | Final Rejection | 10d overdue | Pending | Jun 03, 2022 |
| 17317057 | DETECTION OF AUTOREACTIVE FECAL IMMUNOGLOBULIN A (IGA) FOR DIAGNOSIS OF LUPUS | BALLARD, KIMBERLY | 1675 | §103 | Final Rejection | 34d | Pending | May 11, 2021 |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | DEBERRY, REGINA M | 1647 | DP | Final Rejection | — | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial